Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib 60 mg/day versus 140 mg/day in progressive metastatic medullary thyroid cancer
2024-516480-90-00Phase 4Authorised
- Sponsor
- Exelixis, Inc.
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 4, randomised, double-blind trial of cabozantinib in Medullary Thyroid Cancer (MTC) (2 arms), sponsored by Exelixis, Inc. Primary endpoint: Progression-free survival. Planned start Nov 2015; status: authorised.
02
Drugs
cabozantinib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on 2024-516480-90-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516480-90-00.